Albumin-bound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 9, Issue 3, 2007, Pages 290-299

  Klein, O ^a   Lynge, J ^b   Endahl, L ^b   Damholt, B ^b   Nosek, L ^a   Heise, Tim ^a  

^a PROFIL Institut für Stoffwechselforschung   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Basal insulin analogues; Duration of action; Endogenous glucose production; Glucose clamp; Insulin detemir; Insulin glargine; Type 2 diabetes

Indexed keywords

ALBUMIN; C PEPTIDE; FATTY ACID; HEMOGLOBIN A1C; HUMAN INSULIN; HUMAN INSULIN[B29 LYSINE(N EPSILON LITHOCHOLOYL) B30 GAMMA DEGLUTAMIC ACID]; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; NN 344; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BILIARY COLIC; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; ELECTROCARDIOGRAM; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; GLUCOSE TRANSPORT; HUMAN; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INSULIN BLOOD LEVEL; LABORATORY TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VITAL SIGN;

EID: 33947644300     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00685.x     Document Type: Article

References (35)

1. Starke AA, Heinemann L, Hohmann A, Berger M. The action profiles of human NPH insulin preparations. Diabet Med 1989; 6: 239-244.
2. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002; 4: 673-682.
3. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649.
4. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
5. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: Assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005; 48: 1988-1995.
6. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: The pharmacology of insulin detemir. Int J Obes Relat Metab Disord 2004; 28 (Suppl. 2): S23-S28.
7. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620.
8. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999; 16: 332-338.
9. Brunner GA, Sendhofer G, Wutte A et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes 2000; 108: 100-105.
10. Kurtzhals P, Havelund S, Jonassen I et al. Albumin binding of insulins acylated with fatty acids: Characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995; 312: 725-731.
11. Jonassen I, Havelund S, Ribel U et al. Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives. Pharm Res 2006; 23: 49-55.
12. Lindholm A. New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol 2002; 16: 475-492.
13. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 1959; 82: 420-430.
14. 2] glucose enriched glucose infusion during hyperinsulinaemic euglycaemic clamps. Eur J Clin Invest 1992; 22: 244-253.
15. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28: 1107-1112.
16. Luzio S, Dunseath G, Peter R, Pauvaday V, Owens DR. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 2006; 49: 1163-1168.
17. Vora JP, Burch A, Peters JR, Owens DR. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care 1992; 15: 1484-1493.
18. Vora JP, Burch A, Peters JR, Owens DR. Absorption of radiolabelled soluble insulin in type 1 (insulin-dependent) diabetes: Influence of subcutaneous blood flow and anthropometry. Diabet Med 1993; 10: 736-743.
19. Heise T, Nosek L, Heinemann L et al. Consistent fast onset of action and absorption of insulin glulisine (GLU) in lean to obese subjects [abstract]. Diabetes 2005; 54 (Suppl. 1): 588-P.
20. Gautier JF, Mourier A, de Kerviler E et al. Evaluation of abdominal fat distribution in noninsulin-dependent diabetes mellitus: Relationship to insulin resistance. J Clin Endocrinol Metab 1998; 83: 1306-1311.
21. Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994; 37: 377-380.
22. Jansson PA, Larsson A, Smith U, Lonnroth P. Lactate release from the subcutaneous tissue in lean and obese men. J Clin Invest 1994; 93: 240-246.
23. Rajamand N, Ungerstedt U, Brismar K. Subcutaneous microdialysis before and after an oral glucose tolerance test: A method to determine insulin resistance in the subcutaneous adipose tissue in diabetes mellitus. Diabetes Obes Metab 2005; 7: 525-535.
24. Milicevic Z, Profozic V, Wyatt J et al. Intramuscular injection of insulin lispro or soluble human insulin: Pharmacokinetics and glucodynamics in Type 2 diabetes. Diabet Med 2001; 18: 562-566.
25. Liebl A, Prager R, Kaiser M, Binz K, Gallwitz B. Dosing recommendations for Biphasic Insulin Aspart 30 (BIAsp30), Insulin Detemir (IDet) and Insulin Aspart (IAsp) from the PREFER treat-to-target study. [Abstract]. Diabetes 2006; 55 (Suppl. 1): A460.
26. Lüddeke HJ, Hansen JB, Nauck M. PREDICTIVE: A global, prospective, observational study to evaluate insulin detemir treatment in type 1 and type 2 diabetes. German cohort data [abstract]. Diabetes 2006; 55 (Suppl. 1): 511-P.
27. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med 2006; 23: 879-886.
28. Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002; 347: 1342-1349.
29. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590-596.
30. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (implementing new strategies with insulin glargine for hyperglycaemia treatment) study. Diabet Med 2006; 23: 736-742.
31. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23: 1666-1671.
32. Blumer IR. Severe injection site reaction to insulin detemir. Diabetes Care 2006; 29: 946.
33. Kurtzhals P. How to achieve a predictable basal insulin? Diabetes Metab 2005; 31: 4S25-4S33.
34. Soran H, Younis N. Insulin detemir: A new basal insulin analogue. Diabetes Obes Metab 2006; 8: 26-30.
35. Pieber TR, Treichel HC, Robertson LI, Mordhorst L, Gall MA. Insulin detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycaemia than insulin glargine plus insulin aspart at comparable levels of glycaemic control in type 1 diabetes. (Abstract). Diabetologia 2005; 48 (Suppl. 1): A92.